A csontvelo eredetu CD34+ ossejtek hatása a bal kamra funkciójára akut miokardiális infarktust követoen

Translated title of the contribution: Effects of autologous bone marrow derived CD34+ stem cells on the left ventricular function following myocardial infarction

László Balogh, I. Czuriga, J. Hunyadi, L. Galuska, Éva Kristóf, I. Édes

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Both experimental and human clinical studies executed in the last 5 years suggested that bone marrow derived cells may participate in the healing process after myocardial infarction. A number of small clinical trials indicated mild or moderate beneficial effect of intracoronary administration of bone marrow derived stem cells after myocardial infarction. Most of the studies used mononuclear cell fraction; due to the cellular heterogeneity of this cell population the type of the effective subpopulation was not known. We investigated the safety and functional effects of the autologous bone marrow CD34± stein cells after intracoronary administration in patients with recent myocardial infarction. 8 patients with impaired left ventricular function were transplanted with CD34± bone marrow stein cells 12 ± 1 day after the acute coronary event. 2D-echocardiography, FDG-PET and MIBI-SPECT were performed before transplantation and 6 month later. During the 6-month follow-up the global left ventricular function (basal EF 37,3 ± 2,9%, after cell therapy 44,8 ± 4,1%) and regional viability/metabolism increased significantly (17,6 ± 13,5%). The increase of myocardial perfusion in the infarct region was tendentious but not significant. Our results demonstrate for the first time that the CD34+ subpopulation of bone marrow derived stem cells improves left ventricular function and viability after myocardial infarction.

Original languageHungarian
Pages (from-to)243-249
Number of pages7
JournalOrvosi Hetilap
Volume148
Issue number6
DOIs
Publication statusPublished - Feb 11 2007

Fingerprint

Left Ventricular Function
Stem Cells
Bone Marrow
Myocardial Infarction
Bone Marrow Cells
Population Characteristics
Cell- and Tissue-Based Therapy
Single-Photon Emission-Computed Tomography
Echocardiography
Perfusion
Transplantation
Clinical Trials
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A csontvelo eredetu CD34+ ossejtek hatása a bal kamra funkciójára akut miokardiális infarktust követoen. / Balogh, László; Czuriga, I.; Hunyadi, J.; Galuska, L.; Kristóf, Éva; Édes, I.

In: Orvosi Hetilap, Vol. 148, No. 6, 11.02.2007, p. 243-249.

Research output: Contribution to journalArticle

@article{4f2dfccb3a3242e7b9ad4bc3df0865fd,
title = "A csontvelo eredetu CD34+ ossejtek hat{\'a}sa a bal kamra funkci{\'o}j{\'a}ra akut miokardi{\'a}lis infarktust k{\"o}vetoen",
abstract = "Both experimental and human clinical studies executed in the last 5 years suggested that bone marrow derived cells may participate in the healing process after myocardial infarction. A number of small clinical trials indicated mild or moderate beneficial effect of intracoronary administration of bone marrow derived stem cells after myocardial infarction. Most of the studies used mononuclear cell fraction; due to the cellular heterogeneity of this cell population the type of the effective subpopulation was not known. We investigated the safety and functional effects of the autologous bone marrow CD34± stein cells after intracoronary administration in patients with recent myocardial infarction. 8 patients with impaired left ventricular function were transplanted with CD34± bone marrow stein cells 12 ± 1 day after the acute coronary event. 2D-echocardiography, FDG-PET and MIBI-SPECT were performed before transplantation and 6 month later. During the 6-month follow-up the global left ventricular function (basal EF 37,3 ± 2,9{\%}, after cell therapy 44,8 ± 4,1{\%}) and regional viability/metabolism increased significantly (17,6 ± 13,5{\%}). The increase of myocardial perfusion in the infarct region was tendentious but not significant. Our results demonstrate for the first time that the CD34+ subpopulation of bone marrow derived stem cells improves left ventricular function and viability after myocardial infarction.",
keywords = "Acute myocardial infarction, Heart failure, Stem cell therapy",
author = "L{\'a}szl{\'o} Balogh and I. Czuriga and J. Hunyadi and L. Galuska and {\'E}va Krist{\'o}f and I. {\'E}des",
year = "2007",
month = "2",
day = "11",
doi = "10.1556/OH.2007.27994",
language = "Hungarian",
volume = "148",
pages = "243--249",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "6",

}

TY - JOUR

T1 - A csontvelo eredetu CD34+ ossejtek hatása a bal kamra funkciójára akut miokardiális infarktust követoen

AU - Balogh, László

AU - Czuriga, I.

AU - Hunyadi, J.

AU - Galuska, L.

AU - Kristóf, Éva

AU - Édes, I.

PY - 2007/2/11

Y1 - 2007/2/11

N2 - Both experimental and human clinical studies executed in the last 5 years suggested that bone marrow derived cells may participate in the healing process after myocardial infarction. A number of small clinical trials indicated mild or moderate beneficial effect of intracoronary administration of bone marrow derived stem cells after myocardial infarction. Most of the studies used mononuclear cell fraction; due to the cellular heterogeneity of this cell population the type of the effective subpopulation was not known. We investigated the safety and functional effects of the autologous bone marrow CD34± stein cells after intracoronary administration in patients with recent myocardial infarction. 8 patients with impaired left ventricular function were transplanted with CD34± bone marrow stein cells 12 ± 1 day after the acute coronary event. 2D-echocardiography, FDG-PET and MIBI-SPECT were performed before transplantation and 6 month later. During the 6-month follow-up the global left ventricular function (basal EF 37,3 ± 2,9%, after cell therapy 44,8 ± 4,1%) and regional viability/metabolism increased significantly (17,6 ± 13,5%). The increase of myocardial perfusion in the infarct region was tendentious but not significant. Our results demonstrate for the first time that the CD34+ subpopulation of bone marrow derived stem cells improves left ventricular function and viability after myocardial infarction.

AB - Both experimental and human clinical studies executed in the last 5 years suggested that bone marrow derived cells may participate in the healing process after myocardial infarction. A number of small clinical trials indicated mild or moderate beneficial effect of intracoronary administration of bone marrow derived stem cells after myocardial infarction. Most of the studies used mononuclear cell fraction; due to the cellular heterogeneity of this cell population the type of the effective subpopulation was not known. We investigated the safety and functional effects of the autologous bone marrow CD34± stein cells after intracoronary administration in patients with recent myocardial infarction. 8 patients with impaired left ventricular function were transplanted with CD34± bone marrow stein cells 12 ± 1 day after the acute coronary event. 2D-echocardiography, FDG-PET and MIBI-SPECT were performed before transplantation and 6 month later. During the 6-month follow-up the global left ventricular function (basal EF 37,3 ± 2,9%, after cell therapy 44,8 ± 4,1%) and regional viability/metabolism increased significantly (17,6 ± 13,5%). The increase of myocardial perfusion in the infarct region was tendentious but not significant. Our results demonstrate for the first time that the CD34+ subpopulation of bone marrow derived stem cells improves left ventricular function and viability after myocardial infarction.

KW - Acute myocardial infarction

KW - Heart failure

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=34250160604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250160604&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.27994

DO - 10.1556/OH.2007.27994

M3 - Article

VL - 148

SP - 243

EP - 249

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 6

ER -